Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Neuronal Acetylcholine Receptor Subunit Beta 2 Therapeutics Pipeline Report 2016 - Review of 5 Companies & 11 Molecules - Research and Markets

Research and Markets
Posted on: 20 Sep 16

Research and Markets has announced the addition of the "Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Pipeline Review, H2 2016" report to their offering.

Neuronal Acetylcholine Receptor Subunit Beta 2 pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by Companies and remaining by the Universities/Institutes.

Neuronal Acetylcholine Receptor Subunit Beta 2 - Pipeline Review, H2 2016, outlays comprehensive information targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Neuronal acetylcholine receptor subunit beta-2 is a protein encoded by the CHRNB2 gene. Acetylcholine binds to this receptor. This results in extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions. The molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 4 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Furthermore, this report also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Key Topics Covered:

  1. Introduction
  2. Neuronal Acetylcholine Receptor Subunit Beta 2 Overview
  3. Therapeutics Development
  4. Pipeline Products for Neuronal Acetylcholine Receptor Subunit Beta 2 - Overview
  5. Pipeline Products for Neuronal Acetylcholine Receptor Subunit Beta 2 - Comparative Analysis
  6. Neuronal Acetylcholine Receptor Subunit Beta 2 - Therapeutics under Development by Companies
  7. Neuronal Acetylcholine Receptor Subunit Beta 2 - Therapeutics under Investigation by Universities/Institutes
  8. Neuronal Acetylcholine Receptor Subunit Beta 2 Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Neuronal Acetylcholine Receptor Subunit Beta 2 - Products under Development by Companies
  13. Neuronal Acetylcholine Receptor Subunit Beta 2 - Products under Investigation by Universities/Institutes
  14. Neuronal Acetylcholine Receptor Subunit Beta 2 - Companies Involved in Therapeutics Development
  • Catalyst Biosciences, Inc.
  • H. Lundbeck A/S
  • NeuroDerm Ltd.
  • Saniona AB
  • Suven Life Sciences Ltd.

For more information about this report visit http://www.researchandmarkets.com/research/kq2qhs/neuronal

Related Topics: Central Nervous System Drugs

View source version on businesswire.com: http://www.businesswire.com/news/home/20160920005862/en/

Business Wire
www.businesswire.com

Last updated on: 20/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.